Fluidigm Corp (FLDM) 10.81 $FLDM
Why Fluidigm Corporation is Soaring Higher
Brian Feroldi, The Motley Fool - Motley Fool - Fri Oct 30, 1:13PM CDT
What: Shares of Fluidigm , a company focused on producing tools for the life-science industry, were up more than 35% in early morning trading on higher than normal volume after the company reported earnings results that crushed expectations. So...
FLDM: 10.81 (+3.43)
Fluidigm reports 3Q loss
Automated Insights - Thu Oct 29, 3:47PM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Fluidigm Corp. (FLDM) on Thursday reported a loss of $9.3 million in its third quarter.
FLDM: 10.81 (+3.43)
Fluidigm Reports Q3 2015 Financial Results
Business Wire - Thu Oct 29, 3:00PM CDT
Fluidigm Corporation (NASDAQ:FLDM) today announced its financial results for the third quarter ended September 30, 2015.
FLDM: 10.81 (+3.43)
Leading 200 Global Medical Devices/Technology/Supplies Companies that have Launched New Products
M2 - Thu Oct 22, 2:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qrcc44/global_new) has announced the addition of the "Global New Products Medical Devices/Technology/Supplies 200 " report to their offering. The newly launched report identifies 200 medical devices/technology/supplies companies globally that have launched New Products recently, and covers news of such 200 companies as well as provides details about new products launched by these companies. Medical scientists and physicians are constantly conducting research and testing new procedures to help prevent, diagnose, and cure diseases as well as developing new drugs and new medical products/devices/technology that can lessen symptoms or treat ailments. Profound insight into the companies' value drivers of innovation can release additional, untapped potential. From small innovations like adhesive bandages and ankle braces, to larger, more complex technologies like MRI machines, artificial organs, and robotic prosthetic limbs, technology has undoubtedly made an incredible impact on medicine. Highlights - Leading 200 global medical devices/technology/supplies companies that have launched new products recently covered - Provides detailed summary on new product categories - Summary of other news besides product launch for such companies - Important M&A and alliances of global medical devices/technology/supplies companies with new products - International presence of global medical devices/technology/supplies companies with new products Key Topics Covered: 1: Key New Products Launched by Global Medical Devices/Technology/Supplies Companies 2: Analysis of Global Medical Devices/Technology/Supplies Companies with New Products by Various Attributes 3: Key News of Global Medical Devices/Technology/Supplies Companies with New Products for Year 2014-15 4: Key Alliances of Global Medical Devices/Technology/Supplies Companies with New Products 5: International Presence of Global Medical Devices/Technology/Supplies Companies with New Products 6: Mergers and Acquisitions of Global Medical Devices/Technology/Supplies Companies with New Products Companies Mentioned - Partial List - 3D Systems Corporation - Accuray Inc - Acelity L.P. Inc - Affymetrix, Inc. - Aurora Spine Corp - Avita Medical Limited - AxoGen Inc. - Calgary Scientific Inc. - Cardica, Inc - Cardiocomm Solutions? - Carl Zeiss Meditec AG - Cellavision AB - CloudTag Inc - Cochlear Limited - Cogentix Medical Inc. - Coherent Incorporated - Electromed, Incorporation - Elekta publ AB - Encision Inc - Endologix, Inc. - Entellus Medical Inc - Exactech, Inc. - Exiqon AS - FEI Company - Fisher & Paykel Healthcare Corporation Limited - Fluidigm Corp. - Foundation Medicine Inc. - Fresenius Medical Care AG & Co. KGaA For more information visit http://www.researchandmarkets.com/research/qrcc44/global_new
AXGN: 4.65 (+0.26), DDD: 10.06 (-0.22), ARAY: 6.70 (+0.78), ELGX: 8.54 (-0.24), AFFX: 9.20 (+0.26), FEIC: 72.19 (-1.03), CGNT: 1.27 (-0.08), FMI: 22.42 (+0.26), FLDM: 10.81 (+3.43), ENTL: 16.99 (-0.18), CRDC: 0.20 (-0.03), EXAC: 17.03 (-0.71), COHR: 54.20 (-0.53)
Fluidigm to Announce Q3 2015 Financial Results and Host Conference Call for Investors
Business Wire - Wed Oct 21, 8:00AM CDT
Fluidigm Corporation (NASDAQ:FLDM) will report its third quarter 2015 financial results on October 29, 2015, after close of market.
FLDM: 10.81 (+3.43)
Becton, Dickinson Launches FACSseq Single Cell Sorter
Zacks Equity Research - Zacks Investment Research - Wed Oct 07, 12:00PM CDT
BD, recently announced that its life sciences division has launched "its first dedicated product" which is a high-throughput cell sorter for single cell genomics applications -- BD FACSseq.
BDX: 142.52 (-0.71), FLDM: 10.81 (+3.43), ILMN: 143.28 (-2.44), QGEN: 24.17 (+0.10)
Liquid Biopsy Markets - Global Market Size, Strategies and Forecasts 2015 to 2020
M2 - Mon Sep 14, 6:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5lwdd6/liquid_biopsy) has announced the addition of the "Liquid Biopsy Markets Global Market Size, Strategies and Forecasts 2015 to 2020" report to their offering. Blood Tests replace Surgical Biopsies to create a new multibillion dollar market opportunity..... The Screening Test opportunity is explored New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has outstanding growth potential. The biggest numbers we've seen in the Clinical Diagnostics space. The impact on the health care industry is enormous. The report forecasts the market size out to 2020. In addition the report looks at potential market sizes by country, by cancer and by the three different opportunities: detection, management and screening. This independent research gives you the facts to speak with authority. Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size. The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate and Other Cancers. Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Liquid Biopsy Recent Developments 5. Country Market Sizes - North America 6. Country Markets - Europe 7. Country Markets - Asia Pacific 8. Country Markets - Latin America, Africa & The Middle East 9. Global Market Summary 10. Potential Market Opportunity Sizes Companies Mentioned - ApoCell - AstraZeneca Initiates - BioFluidica - Biocept - Biodesix - Cynvenio - CytoTrack - Cytolumina Technologies Corp - Diagnologix LLC - EGFR Monitoring - EKF Diagnostics - Epic Sciences - European Consortium - Exosome Sciences - Fluidigm Corp - Horizon Discovery - Illumina - Inivata - Inivata Raises - Janssen Diagnostics - LGC - Merck Serono - Qiagen - RainDance Technologies - Rarecells SAS - Roche - Rosetta Genomics - SRI International - SWOG - Silicon Biosystems - Sysmex Inostics - TGen - Tokai - Trovagene For more information visit http://www.researchandmarkets.com/research/5l...uid_biopsy
FLDM: 10.81 (+3.43), MRK: 54.66 (-0.21)
Australia's First Single-Cell Genomics Centre of Excellence Opens at Monash Health Translation Precinct
Business Wire - Thu Sep 03, 4:00PM CDT
A partnership among Monash University, the University of Melbourne, the University of Newcastle and the Hudson Institute of Medical Research, working with single-cell biology leader Fluidigm Corporation (NASDAQ:FLDM), today established Australia's first Single-Cell Genomics Centre of Excellence. The Centre will be housed at Monash Health Translation Precinct's (MHTP) Medical Genomics Facility in Clayton, Victoria, Australia.
FLDM: 10.81 (+3.43)
High Throughput Single-Cell mRNA Sequencing Preparation Comes to the Fluidigm C1 System
Business Wire - Tue Aug 25, 8:00AM CDT
Fluidigm Corporation (NASDAQ:FLDM) today announced commercial availability of a new high throughput single-cell mRNA sequencing workflow for its C1(TM) system to enable large-scale studies to characterize heterogeneous samples. This validated workflow includes a new advanced integrated fluidic circuit (IFC) and reagent kit that significantly increases throughput and ease-of-use, while simultaneously decreasing the cost of preparation and sequencing (by maximizing sequencer capacity) on a per-cell basis. The C1 mRNA Seq HT application is the first and only commercial product to address large single-cell studies and is available today.
FLDM: 10.81 (+3.43)
Microfluidic Devices Market to 2020 - By Material, Polymer Accounts For the Largest Share in the Microfluidics Market
M2 - Thu Aug 20, 3:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xfs3gt/global_industry) has announced the addition of the "Global Industry Insight: Microfluidic Devices Market Development and Demand Forecast to 2020" report to their offering. Microfluidic devices are becoming more and more important for many chemical and biological analyses. Recently there has been an increase in the demand for these devices in proteomics and genomics. With the growth of the low cost genomic devices and further enhancements in microfluidic equipment, an increase in research in biopharmaceuticals is expected. The overall market has also experienced development due to recent product innovations and various industry partnerships and collaborations. On the basis of material, the microfluidic devices market is classified into glass, polymer, silicon and others. Polymer is the main segment of the microfluidic devices market based on material type. By material, polymer accounts the largest share in the microfluidics market and it is expected to grow at a CAGR of 25.7% during the period 2015 to 2020. Report Coverage - Provides comprehensive understanding of the market with the help of informed market outlook, opportunities, challenges, trends, size and growth, competitive analysis, major competitors and Porter analysis - Identifies the key drivers of growth and challenges of the key industry players. Also, assesses the future impact of the propellants and restraints on the market - Provides information on the historical and current market size and the future potential of the market Key Topics Covered: - 1 Research Scope and Methodology - 2 Executive Summary - 3 Market Outlook - 4 Global Market Size and Forecasts (2011 - 2020) - 5 Global Market Breakdown by Industry - 6 Global Market Breakdown by Application - 7 Global Market Breakdown by Material - 8 Global Market Breakdown by Region - 9 Competitive Analysis and Market Share - 10 Company Profiles Companies Mentioned - Abbott Laboratories - Agilent Technologies, Inc. - Becton, Dickinson and Company - Bio-Rad Laboratories, Inc. - Cepheid - Dolomite Centre - F. Hoffmann-La Roche AG - Fluidigm Corporation - Johnson & Johnson - Micronit Microfluidics - RainDance Technologies, Inc. - Siemens Healthcare GmbH For more information visit http://www.researchandmarkets.com/research/xf...l_industry
JNJ: 101.03 (-0.34), ABT: 44.80 (-0.44), FLDM: 10.81 (+3.43), A: 37.76 (+0.06), CPHD: 33.40 (-0.87)
Weakness Seen in Fluidigm (FLDM) Estimates: Should You Stay Away?
Zacks Equity Research - Zacks Investment Research - Tue Aug 18, 7:53AM CDT
Negative earnings estimate revision for current year as well as current quarter makes Fluidigm an underperforming stock
MASI: 39.68 (-0.04), FLDM: 10.81 (+3.43)
Digital PCR (dPCR) and qPCR Market to 2019 - The Market is Estimated to Grow at a CAGR of 7.8% From 2014 to 2019
M2 - Fri Aug 14, 6:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/spldt6/digital_pcr) has announced the addition of the "Digital PCR (dPCR) and qPCR Market by Technology, Product, End User, Application (Research, Diagnostic, Forensic) Global Forecast to 2019" report to their offering. Digital PCR (dPCR) and qPCR Market by Technology, Product (Instruments, Reagents, Software), End User (Research Lab, Academia, Hospitals, Pharmaceutical & Biotechnology Cos, CROs), Application (Research, Diagnostic, Forensic) Global Forecast to 2019 The global digital PCR (dPCR) and qPCR market is estimated to grow at a CAGR of 7.8% from 2014 to 2019. Although the mature markets (such as the U.S., Germany, France, and U.K.) hold larger shares in the digital PCR (dPCR) and qPCR market, the Asia-Pacific region is expected to grow at the highest CAGR of -10.7% in the forecast period. The growth of the digital PCR (dPCR) and qPCR market is driven by factors such as growing geriatric population, technological advancements, rising incidence of infectious diseases and genetic disorders, and increased public-private investments, funds, and grants. In this report, the global digital PCR (dPCR) and qPCR market has been segmented on the basis of type of technology (real-time PCR and digital PCR), type of product (instruments, reagents and consumables, and softwares and services), type of end-users (research laboratories and academic institutes, pharmaceutical and biotechnology companies, hospitals and diagnostic centers, clinical research organizations, and forensic laboratories) applications and type of application (research, clinical, and forensic applications). Companies Mentioned - Agilent Technologies, Inc. - Bio-Rad Laboratories, Inc. - Biom?rieux Sa - Biosistemika, Research And Development Llc - Eppendorf Ag - F. Hoffman-La Roche Ltd. (Switzerland) - Fluidigm Corporation (U.S.) - Geographic Revenue Mix - Qiagen N.V. - Raindance Technologies, Inc. - Takara Bio, Inc. - Thermo Fisher Scientific, Inc. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 By Technology 8 By Product And Services 9 By Application 10 By End User 11 By Region 12 Competitive Landscape 13 Company Profiles For more information visit http://www.researchandmarkets.com/research/sp...igital_pcr
FLDM: 10.81 (+3.43), A: 37.76 (+0.06), QGEN: 24.17 (+0.10)
Fluidigm (FLDM) Stock Plummeting After Earnings Results
at The Street - Fri Aug 07, 11:06AM CDT
Fluidigm (FLDM) stock is falling after the company reported a wider than expected net loss for the 2015 second quarter.
FLDM: 10.81 (+3.43)
Global Microfluids Market Outlook 2020: Fluidigm, Roche, RainDance Technologies, Agilent Technologies, Illumina, Shimadzu, Abbott & GE Healthcare Dominate the $2.5 Billion Industry
M2 - Thu Jul 16, 6:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cssb7d/global) has announced the addition of the "Global Microfluids Market Outlook 2020" report to their offering. The market for healthcare microfluidic devices was worth US$2.5 Billion in 2014 and is poised for a double digit growth during the forecasted period (2014-2020). The healthcare segment is featured with microfluidic applications which refers to the flow of biological liquids through micro channels ranging from nanolitres to few picoltres. This newest approach adds several benefits to the medical world, such as large surface to volume ratio, less reagent consumption, quick diagnosis and high accuracy of the results. Thus, the emerging field of microfluidics or Lab-on-chip' is slowly penetrating into segments like genomics and drug delivery. Though microfluidic devices have the potential to be fast, cheap and portable diagnostic tools, the technology hasn't yet completely made it to the marketplace. The majority of the devices is either in the development stage or meant for research purposes. The latest edition entitled Global Microfluids Market Outlook 2020, describes the overall microfluidics industry landscape with core emphasis on healthcare applications. The new report throws light on the distribution of microfluidics technology by application, type of material and territory. In addition to this, the study covers latest trends capturing the market since last two years. The analysis identified that rising R&D investments, proven accuracy of the microfluidics in point of care diagnostics, and increasing demand in life science research are contributing to the healthy growth of the microfluidics industry. On the contrary, manufacturing difficulties and high capital investment for lab-on-chip devices are two of the major challenges faced by this sector. The key vendors dominating the market space are Fluidigm Corp., Roche, RainDance Technologies, Inc., Agilent Technologies Inc., Illumina, Inc., Shimadzu; Abbott Laboratories; GE Healthcare etc. Finally, the report covers key strengths and weaknesses, and recent developments on the competitive front. Thus, it provides a comprehensive analysis of the microfluidics technology, which will enable investors to design suitable business strategies to target the billion dollar market. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Microfluidics - An Introduction 4. Microfluidics Market Overview 5. Drivers & Challenges 6. Market Segmentation 7. Regulatory Scenario 8. Trends & Developments 9. Competitive Assessment - Abbott Laboratories - Agilent Technologies Inc. - Fluidigm Corporation - GE Healthcare - Illumina Inc. - Perking Elmer - RainDance Technologies - Roche Diagnostics - Shimaduzu - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/cssb7d/global
ABT: 44.80 (-0.44), FLDM: 10.81 (+3.43), A: 37.76 (+0.06), ILMN: 143.28 (-2.44)
Fluidigm (FLDM) and OpGen Extend Strategic Relationship - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 14, 1:05PM CDT
Fluidigm Corp (FLDM) and OpGen recently announced an extension in their strategic relationship.
RTIX: 4.20 (-0.20), FLDM: 10.81 (+3.43), OPGN: 2.12 (-0.03), SURG: 6.69 (+0.09)
Fluidigm and OpGen Enter Into Strategic Agreement to Develop Multi-Drug Resistance Testing Kits and Equipment
GlobeNewswire - Mon Jul 13, 11:00AM CDT
Fluidigm Corporation (NASDAQ:FLDM) and OpGen, Inc. (NASDAQ:OPGN) today announced an expanded relationship and new agreement that includes collaborating on the development of test kits and custom analytic instruments for identification, screening, and surveillance testing of multi-drug resistance organism (MDRO) genes of pathogens, such as bacteria, fungi and viruses.
FLDM: 10.81 (+3.43), OPGN: 2.12 (-0.03)
Why Fluidigm Corporation is Soaring Higher
Brian Feroldi, The Motley Fool - Motley Fool - Fri Oct 30, 1:13PM CDT
What: Shares of Fluidigm , a company focused on producing tools for the life-science industry, were up more than 35% in early morning trading on higher than normal volume after the company reported earnings results that crushed expectations. So...
FLDM: 10.81 (+3.43)
Fluidigm reports 3Q loss
Automated Insights - Thu Oct 29, 3:47PM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Fluidigm Corp. (FLDM) on Thursday reported a loss of $9.3 million in its third quarter.
FLDM: 10.81 (+3.43)
Fluidigm Reports Q3 2015 Financial Results
Business Wire - Thu Oct 29, 3:00PM CDT
Fluidigm Corporation (NASDAQ:FLDM) today announced its financial results for the third quarter ended September 30, 2015.
FLDM: 10.81 (+3.43)
Leading 200 Global Medical Devices/Technology/Supplies Companies that have Launched New Products
M2 - Thu Oct 22, 2:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qrcc44/global_new) has announced the addition of the "Global New Products Medical Devices/Technology/Supplies 200 " report to their offering. The newly launched report identifies 200 medical devices/technology/supplies companies globally that have launched New Products recently, and covers news of such 200 companies as well as provides details about new products launched by these companies. Medical scientists and physicians are constantly conducting research and testing new procedures to help prevent, diagnose, and cure diseases as well as developing new drugs and new medical products/devices/technology that can lessen symptoms or treat ailments. Profound insight into the companies' value drivers of innovation can release additional, untapped potential. From small innovations like adhesive bandages and ankle braces, to larger, more complex technologies like MRI machines, artificial organs, and robotic prosthetic limbs, technology has undoubtedly made an incredible impact on medicine. Highlights - Leading 200 global medical devices/technology/supplies companies that have launched new products recently covered - Provides detailed summary on new product categories - Summary of other news besides product launch for such companies - Important M&A and alliances of global medical devices/technology/supplies companies with new products - International presence of global medical devices/technology/supplies companies with new products Key Topics Covered: 1: Key New Products Launched by Global Medical Devices/Technology/Supplies Companies 2: Analysis of Global Medical Devices/Technology/Supplies Companies with New Products by Various Attributes 3: Key News of Global Medical Devices/Technology/Supplies Companies with New Products for Year 2014-15 4: Key Alliances of Global Medical Devices/Technology/Supplies Companies with New Products 5: International Presence of Global Medical Devices/Technology/Supplies Companies with New Products 6: Mergers and Acquisitions of Global Medical Devices/Technology/Supplies Companies with New Products Companies Mentioned - Partial List - 3D Systems Corporation - Accuray Inc - Acelity L.P. Inc - Affymetrix, Inc. - Aurora Spine Corp - Avita Medical Limited - AxoGen Inc. - Calgary Scientific Inc. - Cardica, Inc - Cardiocomm Solutions? - Carl Zeiss Meditec AG - Cellavision AB - CloudTag Inc - Cochlear Limited - Cogentix Medical Inc. - Coherent Incorporated - Electromed, Incorporation - Elekta publ AB - Encision Inc - Endologix, Inc. - Entellus Medical Inc - Exactech, Inc. - Exiqon AS - FEI Company - Fisher & Paykel Healthcare Corporation Limited - Fluidigm Corp. - Foundation Medicine Inc. - Fresenius Medical Care AG & Co. KGaA For more information visit http://www.researchandmarkets.com/research/qrcc44/global_new
AXGN: 4.65 (+0.26), DDD: 10.06 (-0.22), ARAY: 6.70 (+0.78), ELGX: 8.54 (-0.24), AFFX: 9.20 (+0.26), FEIC: 72.19 (-1.03), CGNT: 1.27 (-0.08), FMI: 22.42 (+0.26), FLDM: 10.81 (+3.43), ENTL: 16.99 (-0.18), CRDC: 0.20 (-0.03), EXAC: 17.03 (-0.71), COHR: 54.20 (-0.53)
Fluidigm to Announce Q3 2015 Financial Results and Host Conference Call for Investors
Business Wire - Wed Oct 21, 8:00AM CDT
Fluidigm Corporation (NASDAQ:FLDM) will report its third quarter 2015 financial results on October 29, 2015, after close of market.
FLDM: 10.81 (+3.43)
Becton, Dickinson Launches FACSseq Single Cell Sorter
Zacks Equity Research - Zacks Investment Research - Wed Oct 07, 12:00PM CDT
BD, recently announced that its life sciences division has launched "its first dedicated product" which is a high-throughput cell sorter for single cell genomics applications -- BD FACSseq.
BDX: 142.52 (-0.71), FLDM: 10.81 (+3.43), ILMN: 143.28 (-2.44), QGEN: 24.17 (+0.10)
Liquid Biopsy Markets - Global Market Size, Strategies and Forecasts 2015 to 2020
M2 - Mon Sep 14, 6:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5lwdd6/liquid_biopsy) has announced the addition of the "Liquid Biopsy Markets Global Market Size, Strategies and Forecasts 2015 to 2020" report to their offering. Blood Tests replace Surgical Biopsies to create a new multibillion dollar market opportunity..... The Screening Test opportunity is explored New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has outstanding growth potential. The biggest numbers we've seen in the Clinical Diagnostics space. The impact on the health care industry is enormous. The report forecasts the market size out to 2020. In addition the report looks at potential market sizes by country, by cancer and by the three different opportunities: detection, management and screening. This independent research gives you the facts to speak with authority. Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size. The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate and Other Cancers. Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Liquid Biopsy Recent Developments 5. Country Market Sizes - North America 6. Country Markets - Europe 7. Country Markets - Asia Pacific 8. Country Markets - Latin America, Africa & The Middle East 9. Global Market Summary 10. Potential Market Opportunity Sizes Companies Mentioned - ApoCell - AstraZeneca Initiates - BioFluidica - Biocept - Biodesix - Cynvenio - CytoTrack - Cytolumina Technologies Corp - Diagnologix LLC - EGFR Monitoring - EKF Diagnostics - Epic Sciences - European Consortium - Exosome Sciences - Fluidigm Corp - Horizon Discovery - Illumina - Inivata - Inivata Raises - Janssen Diagnostics - LGC - Merck Serono - Qiagen - RainDance Technologies - Rarecells SAS - Roche - Rosetta Genomics - SRI International - SWOG - Silicon Biosystems - Sysmex Inostics - TGen - Tokai - Trovagene For more information visit http://www.researchandmarkets.com/research/5l...uid_biopsy
FLDM: 10.81 (+3.43), MRK: 54.66 (-0.21)
Australia's First Single-Cell Genomics Centre of Excellence Opens at Monash Health Translation Precinct
Business Wire - Thu Sep 03, 4:00PM CDT
A partnership among Monash University, the University of Melbourne, the University of Newcastle and the Hudson Institute of Medical Research, working with single-cell biology leader Fluidigm Corporation (NASDAQ:FLDM), today established Australia's first Single-Cell Genomics Centre of Excellence. The Centre will be housed at Monash Health Translation Precinct's (MHTP) Medical Genomics Facility in Clayton, Victoria, Australia.
FLDM: 10.81 (+3.43)
High Throughput Single-Cell mRNA Sequencing Preparation Comes to the Fluidigm C1 System
Business Wire - Tue Aug 25, 8:00AM CDT
Fluidigm Corporation (NASDAQ:FLDM) today announced commercial availability of a new high throughput single-cell mRNA sequencing workflow for its C1(TM) system to enable large-scale studies to characterize heterogeneous samples. This validated workflow includes a new advanced integrated fluidic circuit (IFC) and reagent kit that significantly increases throughput and ease-of-use, while simultaneously decreasing the cost of preparation and sequencing (by maximizing sequencer capacity) on a per-cell basis. The C1 mRNA Seq HT application is the first and only commercial product to address large single-cell studies and is available today.
FLDM: 10.81 (+3.43)
Microfluidic Devices Market to 2020 - By Material, Polymer Accounts For the Largest Share in the Microfluidics Market
M2 - Thu Aug 20, 3:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xfs3gt/global_industry) has announced the addition of the "Global Industry Insight: Microfluidic Devices Market Development and Demand Forecast to 2020" report to their offering. Microfluidic devices are becoming more and more important for many chemical and biological analyses. Recently there has been an increase in the demand for these devices in proteomics and genomics. With the growth of the low cost genomic devices and further enhancements in microfluidic equipment, an increase in research in biopharmaceuticals is expected. The overall market has also experienced development due to recent product innovations and various industry partnerships and collaborations. On the basis of material, the microfluidic devices market is classified into glass, polymer, silicon and others. Polymer is the main segment of the microfluidic devices market based on material type. By material, polymer accounts the largest share in the microfluidics market and it is expected to grow at a CAGR of 25.7% during the period 2015 to 2020. Report Coverage - Provides comprehensive understanding of the market with the help of informed market outlook, opportunities, challenges, trends, size and growth, competitive analysis, major competitors and Porter analysis - Identifies the key drivers of growth and challenges of the key industry players. Also, assesses the future impact of the propellants and restraints on the market - Provides information on the historical and current market size and the future potential of the market Key Topics Covered: - 1 Research Scope and Methodology - 2 Executive Summary - 3 Market Outlook - 4 Global Market Size and Forecasts (2011 - 2020) - 5 Global Market Breakdown by Industry - 6 Global Market Breakdown by Application - 7 Global Market Breakdown by Material - 8 Global Market Breakdown by Region - 9 Competitive Analysis and Market Share - 10 Company Profiles Companies Mentioned - Abbott Laboratories - Agilent Technologies, Inc. - Becton, Dickinson and Company - Bio-Rad Laboratories, Inc. - Cepheid - Dolomite Centre - F. Hoffmann-La Roche AG - Fluidigm Corporation - Johnson & Johnson - Micronit Microfluidics - RainDance Technologies, Inc. - Siemens Healthcare GmbH For more information visit http://www.researchandmarkets.com/research/xf...l_industry
JNJ: 101.03 (-0.34), ABT: 44.80 (-0.44), FLDM: 10.81 (+3.43), A: 37.76 (+0.06), CPHD: 33.40 (-0.87)
Weakness Seen in Fluidigm (FLDM) Estimates: Should You Stay Away?
Zacks Equity Research - Zacks Investment Research - Tue Aug 18, 7:53AM CDT
Negative earnings estimate revision for current year as well as current quarter makes Fluidigm an underperforming stock
MASI: 39.68 (-0.04), FLDM: 10.81 (+3.43)
Digital PCR (dPCR) and qPCR Market to 2019 - The Market is Estimated to Grow at a CAGR of 7.8% From 2014 to 2019
M2 - Fri Aug 14, 6:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/spldt6/digital_pcr) has announced the addition of the "Digital PCR (dPCR) and qPCR Market by Technology, Product, End User, Application (Research, Diagnostic, Forensic) Global Forecast to 2019" report to their offering. Digital PCR (dPCR) and qPCR Market by Technology, Product (Instruments, Reagents, Software), End User (Research Lab, Academia, Hospitals, Pharmaceutical & Biotechnology Cos, CROs), Application (Research, Diagnostic, Forensic) Global Forecast to 2019 The global digital PCR (dPCR) and qPCR market is estimated to grow at a CAGR of 7.8% from 2014 to 2019. Although the mature markets (such as the U.S., Germany, France, and U.K.) hold larger shares in the digital PCR (dPCR) and qPCR market, the Asia-Pacific region is expected to grow at the highest CAGR of -10.7% in the forecast period. The growth of the digital PCR (dPCR) and qPCR market is driven by factors such as growing geriatric population, technological advancements, rising incidence of infectious diseases and genetic disorders, and increased public-private investments, funds, and grants. In this report, the global digital PCR (dPCR) and qPCR market has been segmented on the basis of type of technology (real-time PCR and digital PCR), type of product (instruments, reagents and consumables, and softwares and services), type of end-users (research laboratories and academic institutes, pharmaceutical and biotechnology companies, hospitals and diagnostic centers, clinical research organizations, and forensic laboratories) applications and type of application (research, clinical, and forensic applications). Companies Mentioned - Agilent Technologies, Inc. - Bio-Rad Laboratories, Inc. - Biom?rieux Sa - Biosistemika, Research And Development Llc - Eppendorf Ag - F. Hoffman-La Roche Ltd. (Switzerland) - Fluidigm Corporation (U.S.) - Geographic Revenue Mix - Qiagen N.V. - Raindance Technologies, Inc. - Takara Bio, Inc. - Thermo Fisher Scientific, Inc. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 By Technology 8 By Product And Services 9 By Application 10 By End User 11 By Region 12 Competitive Landscape 13 Company Profiles For more information visit http://www.researchandmarkets.com/research/sp...igital_pcr
FLDM: 10.81 (+3.43), A: 37.76 (+0.06), QGEN: 24.17 (+0.10)
Fluidigm (FLDM) Stock Plummeting After Earnings Results
at The Street - Fri Aug 07, 11:06AM CDT
Fluidigm (FLDM) stock is falling after the company reported a wider than expected net loss for the 2015 second quarter.
FLDM: 10.81 (+3.43)
Global Microfluids Market Outlook 2020: Fluidigm, Roche, RainDance Technologies, Agilent Technologies, Illumina, Shimadzu, Abbott & GE Healthcare Dominate the $2.5 Billion Industry
M2 - Thu Jul 16, 6:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cssb7d/global) has announced the addition of the "Global Microfluids Market Outlook 2020" report to their offering. The market for healthcare microfluidic devices was worth US$2.5 Billion in 2014 and is poised for a double digit growth during the forecasted period (2014-2020). The healthcare segment is featured with microfluidic applications which refers to the flow of biological liquids through micro channels ranging from nanolitres to few picoltres. This newest approach adds several benefits to the medical world, such as large surface to volume ratio, less reagent consumption, quick diagnosis and high accuracy of the results. Thus, the emerging field of microfluidics or Lab-on-chip' is slowly penetrating into segments like genomics and drug delivery. Though microfluidic devices have the potential to be fast, cheap and portable diagnostic tools, the technology hasn't yet completely made it to the marketplace. The majority of the devices is either in the development stage or meant for research purposes. The latest edition entitled Global Microfluids Market Outlook 2020, describes the overall microfluidics industry landscape with core emphasis on healthcare applications. The new report throws light on the distribution of microfluidics technology by application, type of material and territory. In addition to this, the study covers latest trends capturing the market since last two years. The analysis identified that rising R&D investments, proven accuracy of the microfluidics in point of care diagnostics, and increasing demand in life science research are contributing to the healthy growth of the microfluidics industry. On the contrary, manufacturing difficulties and high capital investment for lab-on-chip devices are two of the major challenges faced by this sector. The key vendors dominating the market space are Fluidigm Corp., Roche, RainDance Technologies, Inc., Agilent Technologies Inc., Illumina, Inc., Shimadzu; Abbott Laboratories; GE Healthcare etc. Finally, the report covers key strengths and weaknesses, and recent developments on the competitive front. Thus, it provides a comprehensive analysis of the microfluidics technology, which will enable investors to design suitable business strategies to target the billion dollar market. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Microfluidics - An Introduction 4. Microfluidics Market Overview 5. Drivers & Challenges 6. Market Segmentation 7. Regulatory Scenario 8. Trends & Developments 9. Competitive Assessment - Abbott Laboratories - Agilent Technologies Inc. - Fluidigm Corporation - GE Healthcare - Illumina Inc. - Perking Elmer - RainDance Technologies - Roche Diagnostics - Shimaduzu - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/cssb7d/global
ABT: 44.80 (-0.44), FLDM: 10.81 (+3.43), A: 37.76 (+0.06), ILMN: 143.28 (-2.44)
Fluidigm (FLDM) and OpGen Extend Strategic Relationship - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 14, 1:05PM CDT
Fluidigm Corp (FLDM) and OpGen recently announced an extension in their strategic relationship.
RTIX: 4.20 (-0.20), FLDM: 10.81 (+3.43), OPGN: 2.12 (-0.03), SURG: 6.69 (+0.09)
Fluidigm and OpGen Enter Into Strategic Agreement to Develop Multi-Drug Resistance Testing Kits and Equipment
GlobeNewswire - Mon Jul 13, 11:00AM CDT
Fluidigm Corporation (NASDAQ:FLDM) and OpGen, Inc. (NASDAQ:OPGN) today announced an expanded relationship and new agreement that includes collaborating on the development of test kits and custom analytic instruments for identification, screening, and surveillance testing of multi-drug resistance organism (MDRO) genes of pathogens, such as bacteria, fungi and viruses.
FLDM: 10.81 (+3.43), OPGN: 2.12 (-0.03)
